EP300 and pulmonary arterial hypertension: Specifically, we aimed to (1) define the endothelial-specific contribution of EP300 to PAH pathogenesis, (2) elucidate how EP300-mediated H3K27 acetylation drives transcriptional activation and endothelial dysfunction, and (3) evaluate the therapeutic potential of targeting EP300 in PAH-derived PAECs.